ORCID as entered in ROS

Select Publications
2022, 'Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER plus AR plus breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 83, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2022 - 10 December 2022, http://dx.doi.org/10.1158/1538-7445.SABCS22-P4-08-16
,2021, 'Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 82, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 07 December 2021 - 10 December 2021, http://dx.doi.org/10.1158/1538-7445.SABCS21-PD2-02
,2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982
,2019, 'Abstract GS2-03: The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 80, pp. gs2-03-gs2-03, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.sabcs19-gs2-03
,2019, 'Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700245&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043
,2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001
,2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012
,2018, 'Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-PD7-07
,2017, 'Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 78, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 05 December 2017 - 09 December 2017
,